SCHEMBL25980923

SCHEMBL25980923

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc4c(c3)oc3cccc(-c5ccc(N(c6cccc7ccccc67)c6cccc7ccccc67)cc5)c34)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.36
ALDH1A1 P00352 6/20 0.36
MAPT P10636 6/20 0.36
TSHR P16473 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HPGD P15428 2/20 0.36
ATM Q13315 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TP53 P04637 1/20 0.36
NFKB1 P19838 1/20 0.36
MAPK1 P28482 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
CRHR1 P34998 1/20 0.34
BACE1 P56817 1/20 0.32
POLB P06746 2/20 0.32
HCRTR1 O43613 1/20 0.32
CYP1A2 P05177 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26778853 0.97 KDM4E (0.36) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26778827 0.97 KDM4E (0.36) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26420605 0.94 MAPT (0.35) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL25978293 0.92 MAPT (0.35) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26415598 0.92 MAPT (0.35) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26778658 0.91 MAPT (0.33) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26778637 0.90 ALDH1A1 (0.33) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26420426 0.89 MAPT (0.35) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26420436 0.89 MAPT (0.36) KDM4EALDH1A1MAPTTSHRSMN1; SMN2
SCHEMBL26778857 0.89 MAPT (0.33) KDM4EALDH1A1MAPTTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-11-16 US disclosed
EP-4227301-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 KDM4E 2673/4885ALDH1A1 9/4885MAPT 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.